Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
3.010
-0.160 (-5.05%)
Jul 10, 2026, 4:00 PM EDT - Market closed
Perspective Therapeutics Employees
As of December 31, 2025, Perspective Therapeutics had 166 total employees, including 163 full-time and 3 part-time employees. The number of employees increased by 26 or 18.57% compared to the previous year.
Employees
166
Change (1Y)
26
Growth (1Y)
18.57%
Revenue / Employee
$3,723
Profits / Employee
-$669,476
Market Cap
343.28M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 166 | 26 | 18.57% | 163 | 3 |
| Dec 31, 2024 | 140 | 21 | 17.65% | 138 | 2 |
| Dec 31, 2023 | 119 | 53 | 80.30% | 116 | 3 |
| Jun 30, 2022 | 66 | 5 | 8.20% | 66 | 0 |
| Jun 30, 2021 | 61 | 8 | 15.09% | 61 | 0 |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Varex Imaging | 2,450 |
| Orthofix Medical | 1,605 |
| Treace Medical Concepts | 450 |
| Standard BioTools | 389 |
| Sight Sciences | 186 |
| Electromed | 180 |
| 908 Devices | 172 |
| Delcath Systems | 156 |
CATX News
- 1 day ago - Perspective Therapeutics management to meet virtually with BTIG - TheFly
- 3 days ago - Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. - GlobeNewsWire
- 14 days ago - Perspective Therapeutics management to meet virtually with BTIG - TheFly
- 5 weeks ago - Perspective announces first patient dosed with (212Pb)VMT-alpha-NET - TheFly
- 5 weeks ago - Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study - GlobeNewsWire
- 7 weeks ago - Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma - GlobeNewsWire
- 7 weeks ago - Perspective Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - Perspective Therapeutics doses first patients in two Phase 1/2a studies - TheFly